Get to know our clinical trials
Clinical trial of nilk-2301, a bispecific antibody that binds ceacam5 x cd3, in combination with ni-1801 or nilk-2301 plus standard treatment in pancreatic cancer patients.
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE WHETHER THE STUDY DRUG, NILK-2301 IN COMBINATION WITH NI-1801 OR TREATMENT AS USUAL, HAS POTENTIAL BENEFICIAL EFFECTS AND IS SAFE FOR PATIENTS WITH THIS TYPE OF CANCER.
Codirector
Immunology and Immunotherapy Department
Navarre headquarters
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- AN OPEN-LABEL, PHASE IB, DOSE-ESCALATION, RANDOMIZED DOSE ESCALATION STUDY OF NILK-2301, A BISPECIFIC ANTIBODY THAT BINDS CEACAM5 X CD3, IN COMBINATION WITH NI-1801 (AN ANTIBODY THAT BINDS MESOTHELIN X CD47) OR NILK-2301 PLUS STANDARD TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER OF LOW/MID TUMOR VOLUME ELIGIBLE FOR SECOND-LINE TREATMENT.
- Code EudraCT: 2025-521582-27-00
- Protocol number: LCB-2301-002
- Promoter: Light Chain Bioscience; Novimmune S.A.
- Molecule/Drug: Nilk-2301
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.